RESUMEN
OBJECTIVE: To investigate the use of glutamine administered orally during Methotrexate chemotherapy to prevent oral mucositis and reduce hospital costs in children with acute lymphoblastic leukemia (ALL). METHODS: Twenty-four children received oral glutamine (400 mg/kg body weight per day) and twenty four received placebo on days of chemotherapy administration and for at least 14 additional days. Oral mucositis was graded daily at each day of treatment till completion of therapy. The study groups were compared for the oral mucositis development using the WHO scale. RESULTS: Oral mucositis occurred in 4.2 % of the glutamine group and 62.5% in the placebo group. The use of glutamine was directly associated with prevention of oral mucositis than placebo (OR 0,026; 95% CI: 0,003-0,228). The duration of length hospital stay was lower in the glutamine group than in the placebo group ((8 vs 12 days); p = 0,005). Hospital cost per day for glutamine group was 40 USD per day while placebo group was 48 USD per day. CONCLUSIONS: There was significant difference in the prevention of oral mucositis by oral glutamine vs placebo. The hospital cost for glutamine supplementation was lower than control group.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Glutamina/administración & dosificación , Costos de Hospital/estadística & datos numéricos , Leucemia-Linfoma Linfoblástico de Células Precursoras/tratamiento farmacológico , Estomatitis/tratamiento farmacológico , Administración Oral , Adolescente , Estudios de Casos y Controles , Niño , Preescolar , Femenino , Estudios de Seguimiento , Humanos , Lactante , Masculino , Leucemia-Linfoma Linfoblástico de Células Precursoras/economía , Leucemia-Linfoma Linfoblástico de Células Precursoras/patología , Pronóstico , Estomatitis/inducido químicamente , Estomatitis/economíaRESUMEN
BACKGROUND: Oral mucositis (OM) is an oral toxicity caused by cancer treatment, found often in patients with head and neck cancer. Low-intensity laser therapy for OM has anti-inflammatory, analgesic, and tissue reparative properties. OBJECTIVE: The objective of this work is to perform a systematic review and meta-analysis of the randomized clinical trials of OM laser therapy in patients undergoing treatment for head and neck cancers, followed by a cost-effectiveness analysis of the therapy. METHOD: The search terms, mucositis and phototherapy, laser therapy and mucositis, photobiomodulation and mucositis, and low-level laser therapy and mucositis, were used to search the databases of PubMed, Web of Science, and MEDLINE. Randomized clinical trials were divided into two groups: one treated with laser therapy and the other given a placebo. Only 13 studies were included in the systematic review, and 6 studies in the meta-analysis. RESULTS: The results of the systematic review and meta-analysis show that the laser therapy presented good results in clinical improvement and pain reduction, decreasing the patients' likelihood of developing OM, with degrees of debilitating lesions, to 64% (RR = 0.36 [95% CI = 0.29-0.44]). The cost-effectiveness analysis revealed an incremental cost of R$ 3687.53 for the laser group, with an incremental effectiveness of 132.2. The incremental cost-effectiveness ratio (ICER) was 27.89, for the severe OM cases that were avoided. CONCLUSION: It was concluded, therefore, that photobiomodulation for OM in patients receiving head and neck cancer treatment was clinically effective and cost-effective.
Asunto(s)
Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Neoplasias de Cabeza y Cuello/radioterapia , Terapia por Láser/métodos , Fototerapia/métodos , Estomatitis/terapia , Análisis Costo-Beneficio , Neoplasias de Cabeza y Cuello/economía , Humanos , Terapia por Láser/economía , Fototerapia/economía , Traumatismos por Radiación/economía , Traumatismos por Radiación/etiología , Traumatismos por Radiación/terapia , Ensayos Clínicos Controlados Aleatorios como Asunto/economía , Estomatitis/inducido químicamente , Estomatitis/economía , Estomatitis/etiologíaRESUMEN
PURPOSE: Limited data about oral mucositis (OM) in stem cell transplant patients with underlying hematological disease is available in Germany. The purpose of this feasibility study was to determine the incidence, treatment patterns, patients' adherence, and costs of OM. METHODS: Prospective, noninterventional single-center observational study. INCLUSION CRITERIA: allogenic/autologous stem cell transplant patients ≥ 18 years, high-dose chemotherapy. OM assessment: WHO Oral Toxicity Scale. Adherence was measured in patient interviews. Preventive and therapeutic measures were extracted from patients' charts. RESULTS: Forty-five patients (25 allogenic, 20 autologous) were enrolled. Twenty-six (58%) patients developed OM (54% grade I/II, 46% grade III/IV). Age ≥ 65 (31% vs 69%, p = 0.021) was associated with a lower OM incidence. A positive history of smoking (1.77 vs 2.69, p = 0.036) was associated with a lower OM grade, patients with unrelated donors (2.63 vs 1.29, p = 0.014) were associated with higher OM grades and females (80% vs 47%, RR = 1.71, p = 0.035) with a higher incidence. OM patients were less adherent to recommended daily mouth rinses (35% vs 68%, p = 0.027). More analgesic treatment (80% vs 32%, p = 0.001) and intravenous opioids (24% vs 0%, p = 0.023) were prescribed in OM patients. Total drug treatment and nutrition costs were 824 (p = 0.037) higher in autologous transplanted patients. CONCLUSION: Initial risk and consecutive OM assessment, determination of patients' adherence, resource consumption, and costs are prerequisites to evaluate OM care. In the best case, several centers will follow the same methodological approach and the collected data will serve as a basis for benchmarking analyses to optimize OM care where required.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas/estadística & datos numéricos , Estomatitis/epidemiología , Adulto , Costo de Enfermedad , Estudios de Factibilidad , Femenino , Alemania/epidemiología , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Trasplante de Células Madre Hematopoyéticas/economía , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Antisépticos Bucales/administración & dosificación , Cooperación del Paciente/estadística & datos numéricos , Estudios Prospectivos , Índice de Severidad de la Enfermedad , Estomatitis/tratamiento farmacológico , Estomatitis/economía , Estomatitis/etiología , Trasplante Autólogo , Adulto JovenRESUMEN
Oral mucositis is one of the most frequent complications after chemotherapy or radiotherapy or a combination of both. There is no standard therapy for its prevention or treatment. Considering that some bee products have been found to be of value in this situation, we decided to analyze the scientific literature on the subject. Scientific publications on bee products were identified by a literature search on Pubmed, Scopus and Google Scholar. There is a lot of evidence regarding the use of honey for oral mucositis due to chemotherapy or radiotherapy or a combination of both. Unfortunately, the quality of several meta-analyses on the topic is very low. There is some evidence on propolis, a little on royal jelly and none whatsoever on pollen and other bee products like apilarnil or bee venom. Bee products such as honey, propolis and royal jelly may be well suited to be integrated into a general concept for the prevention and treatment of oral mucositis which should also include other established concepts like oral care, oral cryotherapy, topical vitamin E and low-level-laser therapy. Bee products could become an integral part in the treatment of chemotherapy, radiotherapy and radio chemotherapy. High-quality meta-analyses and further studies, especially on the combinations of various strategies, are needed.
Asunto(s)
Abejas/química , Estomatitis/economía , Estomatitis/prevención & control , Administración Tópica , Animales , Ácidos Grasos/administración & dosificación , Ácidos Grasos/uso terapéutico , Miel , Humanos , Neoplasias/tratamiento farmacológico , Neoplasias/radioterapia , Própolis/administración & dosificación , Própolis/uso terapéutico , Vitamina E/administración & dosificación , Vitamina E/uso terapéuticoRESUMEN
BACKGROUND: Oral mucositis (OM) is the most frequent and debilitating acute side effect associated with head and neck cancer (HNC) treatment. When present, severe OM negatively impacts the quality of life of patients undergoing HNC treatment. Photobiomodulation is a well-consolidated and effective therapy for the treatment and prevention of severe OM, and is associated with a cost reduction of the cancer treatment. Although an increase in the quality of life and a reduction in the severity of OM are well described, there is no study on cost-effectiveness for this approach considering the quality of life as a primary outcome. In addition, little is known about the photobiomodulation effects on salivary inflammatory mediators. Thus, this study aimed to assess the cost-effectiveness of the photobiomodulation therapy for the prevention and control of severe OM and its influence on the salivary inflammatory mediators. METHODS/DESIGN: This randomized, double-blind clinical trial will include 50 HNC patients undergoing radiotherapy or chemoradiotherapy. The participants will be randomized into two groups: intervention group (photobiomodulation) and control group (preventive oral care protocol). OM (clinical assessment), saliva (assessment of collected samples) and quality of life (Oral Health Impact Profile-14 and Patient-Reported Oral Mucositis Symptoms questionnaires) will be assessed at the 1st, 7th, 14th, 21st and 30th radiotherapy sessions. Oxidative stress and inflammatory cytokine levels will be measured in the saliva samples of all participants. The costs are identified, measured and evaluated considering the radiotherapy time interval. The incremental cost-effectiveness ratio will be estimated. The study will be conducted according to the Brazilian public health system perspective. DISCUSSION: Photobiomodulation is an effective therapy that reduces the cost associated with OM treatment. However, little is known about its cost-effectiveness, mainly when quality of life is the effectiveness measure. Additionally, this therapy is not supported by the Brazilian public health system. Therefore, this study widens the knowledge about the safety of and strengthens evidence for the use of photobiomodulation therapy, providing information for public policy-makers and also for dental care professionals. This study is strongly encouraged due to its clinical relevance and the possibility of incorporating new technology into public health systems. TRIAL REGISTRATION: Brazilian Registry of Clinical Trials-ReBEC, RBR-5h4y4n . Registered on 13 June 2017.
Asunto(s)
Quimioradioterapia/efectos adversos , Irradiación Craneana/efectos adversos , Neoplasias de Cabeza y Cuello/radioterapia , Terapia por Luz de Baja Intensidad/métodos , Traumatismos por Radiación/prevención & control , Glándulas Salivales/efectos de la radiación , Estomatitis/prevención & control , Biomarcadores/metabolismo , Brasil , Quimioradioterapia/economía , Análisis Costo-Beneficio , Irradiación Craneana/economía , Citocinas/metabolismo , Método Doble Ciego , Neoplasias de Cabeza y Cuello/economía , Costos de la Atención en Salud , Humanos , Mediadores de Inflamación/metabolismo , Terapia por Luz de Baja Intensidad/efectos adversos , Terapia por Luz de Baja Intensidad/economía , Estrés Oxidativo , Traumatismos por Radiación/economía , Traumatismos por Radiación/etiología , Traumatismos por Radiación/metabolismo , Ensayos Clínicos Controlados Aleatorios como Asunto , Factores de Riesgo , Saliva/metabolismo , Glándulas Salivales/metabolismo , Índice de Severidad de la Enfermedad , Estomatitis/economía , Estomatitis/etiología , Estomatitis/metabolismo , Factores de Tiempo , Resultado del TratamientoRESUMEN
BACKGROUND: Surprisingly little is known about the burden of oral mucositis (OM). We provide a systematic review of studies on the burden of OM (incidence, economic impact, health-related quality of life (HRQoL)). METHODS: Systematic literature searches were made in BIOSIS, EMBASE, and MEDLINE. Inclusion criteria were studies on OM in hematology/oncology patients of ≥ 18 years, journal articles, English language, and published between 2000 and 2016; OM treatment studies were excluded. Quality assessment was performed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. RESULTS: We screened 4,996 hits, and identified 68 studies of which 13 were without transparency on OM grading. The evidence level of 65 studies was rated 'low' or 'very low' in 58.5%, 'moderate' in 20% and 'high' in 21.5%. Mean value of incidence (7 studies) was 83.5% for all grades of OM with hematopoietic stem cell transplantation. OM incidence for all grades in head and neck cancer patients was 59.4-100%. Considering the economic impact, 16 studies showed highly variable numbers. HRQoL was measured in 16 studies using 13 different instruments. Statistically significant changes in HRQoL scores were demonstrated. CONCLUSION: OM is common, burdensome, costly and imposes major reductions in HRQoL. However, from a quality standpoint, the level of current evidence in OM is disappointing. The field needs continued attention to address methodological challenges.
Asunto(s)
Costo de Enfermedad , Neoplasias de Cabeza y Cuello/complicaciones , Trasplante de Células Madre Hematopoyéticas/métodos , Estomatitis/terapia , Investigación Biomédica/métodos , Investigación Biomédica/tendencias , Predicción , Humanos , Calidad de Vida , Estomatitis/complicaciones , Estomatitis/economíaRESUMEN
PURPOSE: Busulfan (BU) used as cytoreductive conditioning prior to hematopoietic stem cell transplantation (HSCT) is available as intravenous (IV) and oral (O) preparation. IV-BU has clinical advantages associated with relevant incremental costs. The aim was to determine the economic impact of IV-BU versus O-BU in adult HSCT recipients from a German health care providers' perspective. METHODS: A budget-impact model (BIM) including costs and risks for oral mucositis (OM), infection with OM, and hepatic sinusoidal obstruction syndrome (SOS) was developed. Model inputs are literature data comparing clinical effects of IV-BU versus O-BU and German cost data (conditioning therapy, treatment of OM, infections, SOS without/with multiorgan failure) from literature and tariff lists. RESULTS: Base case calculations resulted the following: total costs of adverse events were 86,434 with O-BU and 44,376 with IV-BU for ten patients each. Considering costs of adverse events and drugs, about 5840 for ten patients receiving IV-BU are saved. Sensitivity analyses were conducted in several ways. Cost savings range between 4910 and 12,640 per ten patients for all adverse events and 2070 or 1140 per ten patients considering SOS only. Drug treatment of SOS and treatment of multiorgan failure during severe SOS are major cost drivers. Worst case scenario calculations (assuming -25% risk of all adverse events for O-BU and +25% for IV-BU) yield up to 27,570 per ten patients with IV-BU. CONCLUSIONS: Considering costs of adverse events and drugs, IV-BU is the dominant alternative from a German providers' perspective. For more comprehensive economic evaluations, additional epidemiological data, evidence on clinical outcomes, patient-reported outcomes, and treatment patterns are needed.
Asunto(s)
Administración Intravenosa/economía , Busulfano/administración & dosificación , Busulfano/economía , Trasplante de Células Madre Hematopoyéticas , Acondicionamiento Pretrasplante/economía , Administración Oral , Adulto , Anciano , Busulfano/efectos adversos , Costos de los Medicamentos , Femenino , Alemania/epidemiología , Neoplasias Hematológicas/economía , Neoplasias Hematológicas/epidemiología , Neoplasias Hematológicas/terapia , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Trasplante de Células Madre Hematopoyéticas/economía , Enfermedad Veno-Oclusiva Hepática/inducido químicamente , Enfermedad Veno-Oclusiva Hepática/economía , Enfermedad Veno-Oclusiva Hepática/epidemiología , Humanos , Modelos Econométricos , Estomatitis/inducido químicamente , Estomatitis/economía , Estomatitis/epidemiología , Acondicionamiento Pretrasplante/efectos adversos , Acondicionamiento Pretrasplante/métodos , Trasplante HomólogoRESUMEN
OBJECTIVE: The aim of this study was to explore whether management of mucositis with Chlorhexidine (CHX) mouthwash could be a cost-effective method to decrease the risk of mortality and economic burden in hemato-oncologic or hematopoietic stem cell transplantation (HSCT) patients. METHODS: A cost-effectiveness analysis model of prophylactic CHX mouthwash use versus no-CHX mouthwash use for the prevention of oral mucositis was developed for patients undergoing cytotoxic therapy or HSCT. The outcome variable was survival. The primary variables were CHX mouthwash use, probability of mucositis, probability of increased hospital stay, and length of hospital stay. Probability and cost data were obtained from the literature. RESULTS: Our analysis selected CHX mouthwash use during anticancer treatment as the preferred strategy for the base-case analysis as compared to no CHX mouthwash (marginal value 0.032). There was a $14,391 cost difference per patient between the two strategies. CONCLUSION: The results of this study suggest that CHX mouthwash use during anticancer treatment results in an increased survival and decreased cost for the population studied. Using our base-case data, an additional 32 of every 1,000 hemato-oncologic or HSCT patients will survive when employing the preferred strategy of prophylactic CHX mouthwash. CLINICAL RELEVANCE: CHX mouthwash should be offered for hematologic patients undergoing HSCT or administered with chemotherapy.
Asunto(s)
Clorhexidina , Neoplasias Hematológicas , Antisépticos Bucales , Estomatitis , Administración Tópica , Adulto , Clorhexidina/administración & dosificación , Clorhexidina/economía , Costos y Análisis de Costo , Supervivencia sin Enfermedad , Femenino , Neoplasias Hematológicas/economía , Neoplasias Hematológicas/mortalidad , Neoplasias Hematológicas/terapia , Humanos , Masculino , Antisépticos Bucales/administración & dosificación , Antisépticos Bucales/economía , Factores de Riesgo , Estomatitis/economía , Estomatitis/mortalidad , Estomatitis/prevención & control , Tasa de SupervivenciaRESUMEN
Oral mucositis (OM) is one of the side effects of hematopoietic stem cell transplantation (HSCT), resulting in major morbidity. The aim of this study was to determine the cost-effectiveness of the introduction of a specialized oral care program including laser therapy in the care of patients receiving HSCT with regard to morbidity associated with OM. Clinical information was gathered on 167 patients undergoing HSCT and divided according to the presence (n = 91) or absence (n = 76) of laser therapy and oral care. Cost analysis included daily hospital fees, parenteral nutrition (PN) and prescription of opioids. It was observed that the group without laser therapy (group II) showed a higher frequency of severe degrees of OM (relative risk = 16.8, 95% confidence interval -5.8 to 48.9, p < 0.001), with a significant association between this severity and the use of PN (p = 0.001), prescription of opioids (p < 0.001), pain in the oral cavity (p = 0.003) and fever > 37.8°C (p = 0.005). Hospitalization costs in this group were up to 30% higher. The introduction of oral care by a multidisciplinary staff including laser therapy helps reduce morbidity resulting from OM and, consequently, helps minimize hospitalization costs associated with HSCT, even considering therapy costs.
Asunto(s)
Trasplante de Células Madre Hematopoyéticas/efectos adversos , Terapia por Luz de Baja Intensidad , Infecciones Oportunistas/prevención & control , Higiene Bucal/métodos , Estomatitis/terapia , Acondicionamiento Pretrasplante/efectos adversos , Adulto , Anciano , Aloinjertos/economía , Antibacterianos/administración & dosificación , Antibacterianos/economía , Antibacterianos/uso terapéutico , Profilaxis Antibiótica/economía , Antifúngicos/administración & dosificación , Antifúngicos/economía , Antifúngicos/uso terapéutico , Protocolos de Quimioterapia Combinada Antineoplásica/economía , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Brasil , Estudios de Casos y Controles , Análisis Costo-Beneficio , Odontólogos/economía , Costos de los Medicamentos , Femenino , Trasplante de Células Madre Hematopoyéticas/economía , Costos de Hospital , Hospitalización/economía , Humanos , Huésped Inmunocomprometido , Inmunosupresores/efectos adversos , Inmunosupresores/economía , Inmunosupresores/uso terapéutico , Terapia por Luz de Baja Intensidad/economía , Terapia por Luz de Baja Intensidad/métodos , Masculino , Persona de Mediana Edad , Agonistas Mieloablativos/economía , Agonistas Mieloablativos/uso terapéutico , Narcóticos/economía , Narcóticos/uso terapéutico , Infecciones Oportunistas/economía , Infecciones Oportunistas/etiología , Higiene Bucal/economía , Nutrición Parenteral/economía , Grupo de Atención al Paciente , Estudios Retrospectivos , Autocuidado/economía , Estomatitis/economía , Estomatitis/etiología , Estomatitis/prevención & control , Acondicionamiento Pretrasplante/economía , Trasplante Autólogo/economíaRESUMEN
Side effects or toxicities are frequent, undesirable companions of almost all forms of non-surgical cancer therapy. It is unusual for patients to complete treatment with radiation or chemotherapy without experiencing at least one form of therapy-associated tissue injury or systemic side effect. Often, toxicities do not occur as solitary events; rather, they result in clusters of symptoms that share a common biological aetiology. Like any disease, cancer treatment-related toxicities (CTRTs) vary in their severity. But, in contrast to most diseases in which incidence is described as being present or absent, the current approach to CTRT typically limits reporting to severe cases only. Not only does this dilute the frequency with which CTRTs occur, but it also undermines our ability to determine the full burden of their impact and to accurately assess the cost effectiveness of potential toxicity interventions. In this article, we report the results of a directed literature review for the years 2000-2012, in which we studied and compared three tissue-based toxicities (nausea and vomiting, diarrhoea, and oral mucositis) and one systemic toxicity (fatigue). Our results confirm the heavy burden of resource use and cost associated with CTRTs. The inclusion of fatigue in our analysis provided an opportunity to compare and contrast a toxicity in which there are both acute and chronic consequences. Our findings also demonstrate a number of challenges to, and opportunities for, future study. Among the most obvious are the lack of provider consistency in diagnosis and grading, especially when there is no global agreement on severity scales. Compounding this inconsistency is the disconnect between healthcare providers and patients that exists when describing toxicity severity and impact. In many cases, cancer can be thought of as a chronic disease that requires prolonged but episodic treatment once the acute disease is eradicated. This change reflects increasing treatment successes, but it also implies that the burden of CTRTs will be expanded and prolonged. Creation of hierarchical attribution of costs in the presence of simultaneous CTRTs, accurate coding, and consistent tracking tools for toxicities will be imperative for effective appraisal of the costs associated with cancer treatment regimen toxicities.
Asunto(s)
Antineoplásicos/efectos adversos , Diarrea/economía , Fatiga/economía , Costos de la Atención en Salud , Náusea/economía , Radioterapia/efectos adversos , Estomatitis/economía , Vómitos/economía , Antineoplásicos/economía , Diarrea/inducido químicamente , Fatiga/inducido químicamente , Humanos , Náusea/inducido químicamente , Neoplasias/tratamiento farmacológico , Neoplasias/economía , Neoplasias/radioterapia , Radioterapia/economía , Estomatitis/inducido químicamente , Vómitos/inducido químicamenteRESUMEN
Oral mucositis (OM) is a painful and debilitating complication of cancer therapy that can adversely affect patients' treatment regimens and quality of life. It is also considered to be a substantial burden on the financial and human resources of health services. Despite progress in the understanding of the pathophysiology of OM and the number of new treatments that have been developed, there remains an unmet need for effective preventative measures in clinical practice. Literature on oral healthcare management in oncology patients suggests that a preventative approach consisting of a supersaturated Ca2+ / PO4(3-) oral rinse (Caphosol(®)) aimed at maintaining oral hygiene, moistening and lubricating the oral cavity, effectively reduces the incidence and severity of OM. This review looked at data from all known adult and paediatric studies investigating the use of Caphosol(®) in patients receiving high-dose cancer therapy in order to evaluate its efficacy for both the prevention and treatment of OM. Thirty studies were identified. The majority of these studies (n = 24) found Caphosol(®) to be efficacious at reducing the grade and/or duration, as well as pain associated with OM. Despite important limitations, these data warrant serious consideration for the inclusion of Caphosol(®) in regimens for preventing or reducing the debilitating effects of OM.
Asunto(s)
Antineoplásicos/efectos adversos , Fosfatos de Calcio/administración & dosificación , Mucosa Bucal/efectos de la radiación , Antisépticos Bucales/administración & dosificación , Traumatismos por Radiación/prevención & control , Estomatitis/prevención & control , Administración Oral , Antineoplásicos/economía , Fosfatos de Calcio/economía , Ahorro de Costo , Nutrición Enteral/estadística & datos numéricos , Métodos Epidemiológicos , Humanos , Tiempo de Internación , Antisépticos Bucales/economía , Neoplasias/tratamiento farmacológico , Neoplasias/radioterapia , Dolor/prevención & control , Satisfacción del Paciente , Radioterapia/efectos adversos , Estomatitis/economía , Estomatitis/etiología , Resultado del TratamientoRESUMEN
Of the toxicities associated with conventional forms of treatment for head and neck cancers, probably none has such a consistent legacy as oral mucositis.1 Despite the fact that mucosal injury was noted as far back as Marie Curie's first forays into therapeutic radiation, an effective intervention has yet to be developed. In addition to its historic link to radiation, new therapeutic strategies including induction chemotherapy often produce mucositis, and targeted therapies appear to alter mucositis risk and its severity and course.2 The symptomatic effect of oral mucositis is profound. Disabling oral and oropharyngeal pain prevents patients from eating normally, requires opiate analgesics, and in some cases results in alteration or discontinuation of anticancer therapy.3 Furthermore, the health and economic consequences of oral mucositis are far from trivial. The incremental cost of oral mucositis in patients with head and neck cancer exceeds $17,000 (USD).4.
Asunto(s)
Antineoplásicos/efectos adversos , Neoplasias de Cabeza y Cuello/terapia , Traumatismos por Radiación/etiología , Estomatitis/etiología , Animales , Antineoplásicos/economía , Neoplasias de Cabeza y Cuello/economía , Costos de la Atención en Salud , Humanos , Traumatismos por Radiación/diagnóstico , Traumatismos por Radiación/economía , Traumatismos por Radiación/terapia , Radioterapia/efectos adversos , Radioterapia/economía , Factores de Riesgo , Estomatitis/inducido químicamente , Estomatitis/diagnóstico , Estomatitis/economía , Estomatitis/terapia , Resultado del TratamientoRESUMEN
Oral mucosal damage is one of the common and worst side effects of radiotherapy and chemotherapy treatment for cancer. With prevalence between 10% and 100%, depending on the cytotoxic and/or radiotherapy regimen and patient-associated variables, this morbid condition represents a significant problem in oncology. This article addresses oral mucositis and discusses its prevalence, risk factors, clinical and economical impacts, etiology, and clinical management in view of the most recent evidence. Despite clear progress and the development of clinical guidelines on this topic, what we currently have to offer to patients to manage mucositis and oropharyngeal pain is still inadequate. This article offers two compounded preparations supported by evidence-based data to treat oral mucositis. Expansion of the knowledge of the pathogenesis of mucositis as well as a better insight into individual risk factors will provide opportunities to improve management strategies.
Asunto(s)
Estomatitis/tratamiento farmacológico , Estomatitis/etiología , Antineoplásicos/efectos adversos , Composición de Medicamentos , Humanos , Guías de Práctica Clínica como Asunto , Radioterapia/efectos adversos , Factores de Riesgo , Estomatitis/economía , Irradiación Corporal Total/efectos adversosRESUMEN
Oral mucositis remains one of the most common and troubling side effects of standard chemoradiation regimens used for the treatment of head and neck cancer. Virtually all patients who receive cumulative radiation doses of more than 30 Gy that includes oral mucosal fields will develop the condition. Not only does mucositis cause extreme discomfort, often necessitating opioid analgesia, but it is also associated with increased use of health resources and cost of treatment. The incremental cost of mucositis in patients with head and neck cancer is more than $17 000 (US). Much has been learned about the pathobiology that underlies the condition. The departure from the historical paradigm of direct cell death as being the primary cause for mucosal injury in favor of a more comprehensive view of the impact of chemoradiation on all the cells of the mucosa, has resulted in a picture of mucositis pathogenesis, which is biologically broad based. Although there are currently few treatment options for oral mucositis at the moment, the recognition that its underlying biology is complex has provided a range of treatment options that are currently being developed.
Asunto(s)
Antineoplásicos/efectos adversos , Traumatismos por Radiación/patología , Estomatitis/etiología , Animales , Antineoplásicos/uso terapéutico , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Neoplasias de Cabeza y Cuello/radioterapia , Costos de la Atención en Salud , Humanos , Dosis de Radiación , Traumatismos por Radiación/economía , Traumatismos por Radiación/terapia , Estomatitis/economía , Estomatitis/patología , Estomatitis/terapiaRESUMEN
The paper estimates socioeconomic conditions (the population's income levels) in the Nizhni Novgorod Region in 2004-2006 and analyzes the results of studying skin microbial resistance and local immunity of the oral cavity in children from good and poor social groups in the towns of Arzamas and Shatki.
Asunto(s)
Estado de Salud , Inmunidad Celular , Mucosa Bucal/inmunología , Enfermedades Cutáneas Bacterianas/economía , Piel/inmunología , Estomatitis/economía , Adolescente , Bacterias/crecimiento & desarrollo , Niño , Preescolar , Recuento de Colonia Microbiana , Humanos , Lactante , Pruebas de Sensibilidad Microbiana/métodos , Mucosa Bucal/microbiología , Prevalencia , Estudios Retrospectivos , Factores de Riesgo , Federación de Rusia/epidemiología , Piel/microbiología , Enfermedades Cutáneas Bacterianas/epidemiología , Enfermedades Cutáneas Bacterianas/inmunología , Factores Socioeconómicos , Estomatitis/epidemiología , Estomatitis/inmunologíaRESUMEN
This article explores the psychosocial and economic implications of cancer and their relevance to the clinician. After a general overview of the topic, the authors focus on aspects of particular importance to the dental professional, including the psychosocial and economic implications of the oral complications of cancer and its therapy, head and neck cancers, and special issues among children with cancer and cancer survivors.
Asunto(s)
Neoplasias/psicología , Calidad de Vida , Antineoplásicos/efectos adversos , Antineoplásicos/economía , Niño , Dolor Facial/psicología , Dolor Facial/terapia , Familia , Neoplasias de Cabeza y Cuello/complicaciones , Neoplasias de Cabeza y Cuello/economía , Neoplasias de Cabeza y Cuello/psicología , Humanos , Seguro de Salud/economía , Neoplasias/complicaciones , Neoplasias/economía , Radioterapia/efectos adversos , Radioterapia/economía , Estomatitis/economía , Estomatitis/etiología , Análisis de SupervivenciaRESUMEN
Mucositis is a common complication of cancer therapy and can be a debilitating and dose-limiting toxicity. Nearly all patients with head and neck cancer treated with radiotherapy develop some degree of mucositis, as do the majority of patients undergoing high-dose chemotherapy in conjunction with hematopoietic stem cell transplantation. Mucositis can have significant clinical and economic consequences. It is associated with severe pain that requires opioid analgesics and often results in the loss of critical functions such as speech and swallowing. Swallowing difficulties can lead to dehydration, weight loss, and the need for nutritional support. Furthermore, patients with mucositis are at increased risk of infection. Unscheduled dose reductions or treatment breaks due to severe mucositis may potentially compromise the efficacy of therapy and result in diminished quality of life. Treatment costs for patients with mucositis are substantially higher due to increased rates of hospitalization, opioid use, and a greater need for fluids and nutritional support. Costs generally increase as a function of mucositis severity. Effective treatments to prevent or reduce the incidence and severity of mucositis are needed to decrease function loss, minimize symptom burden, and lower treatment costs.
Asunto(s)
Antineoplásicos/efectos adversos , Neoplasias de Cabeza y Cuello/terapia , Costos de la Atención en Salud , Radioterapia/efectos adversos , Estomatitis/diagnóstico , Estomatitis/etiología , Neoplasias de Cabeza y Cuello/tratamiento farmacológico , Neoplasias de Cabeza y Cuello/radioterapia , Humanos , Pronóstico , Estomatitis/economía , Pérdida de PesoRESUMEN
The purpose of this study was to assess the relationship between oral mucositis (OM) and adverse clinical and economic outcomes of autologous hematopoietic stem-cell transplantation (HSCT) following high-dose melphalan (Alkeran) conditioning in patients with multiple myeloma. A retrospective study of 115 consecutive autologous HSCT recipients with multiple myeloma who received high-dose melphalan conditioning before transplantation was undertaken at a single academic center. OM severity was assessed twice weekly using a validated scale beginning 3-4 days following conditioning and continuing until hospital discharge or day 28, whichever occurred first. OM was graded, based on presence/extent of erythema/ulceration across eight oropharyngeal sites, as follows: 0 = no erythema or ulceration; I = erythema but no ulceration; II = ulceration, 1 site; III = ulceration, 2 sites; IV = ulceration, 3 sites; and V = ulceration, > or = 4 sites. Analyses examined the relationship between worst OM grade and selected clinical and economic outcomes, including days with fever, days of total parenteral nutrition (TPN),days of parenteral narcotic therapy, incidence of significant infection, and inpatient days and charges. The mean age of study subjects was 54 years; 19 patients (17%) received total-body irradiation, and 55 patients (48%) experienced OM grade > or = II (ie, ulceration). The worst OM grade was significantly (P < 0.05) associated with numbers of days of TPN and parenteral narcotic therapy, length of hospitalization, and total inpatient charges. Worst OM grade was not associated with the number of febrile days or the risk of significant infection. OM is associated with worse clinical and economic outcomes in multiple myeloma patients undergoing autologous HSCT following high-dose melphalan conditioning.
Asunto(s)
Antineoplásicos Alquilantes/efectos adversos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Melfalán/efectos adversos , Mieloma Múltiple/terapia , Estomatitis/inducido químicamente , Acondicionamiento Pretrasplante/efectos adversos , Análisis de Varianza , Boston , Costos y Análisis de Costo , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Tiempo de Internación/economía , Masculino , Persona de Mediana Edad , Úlceras Bucales/inducido químicamente , Úlceras Bucales/economía , Úlceras Bucales/terapia , Nutrición Parenteral Total/economía , Estudios Retrospectivos , Índice de Severidad de la Enfermedad , Estomatitis/economía , Estomatitis/terapia , Factores de Tiempo , Trasplante Autólogo/efectos adversos , Resultado del TratamientoRESUMEN
A double-blind, randomized trial showed that, compared with placebo, palifermin (recombinant human keratinocyte growth factor) reduced the frequency and duration of oral mucositis in patients with hematologic malignancies undergoing high-dose chemotherapy and total-body irradiation with autologous stem-cell support. This previously published study also showed a significant reduction in the incidence of adverse subsequent outcomes. The objective of this study was to estimate the impact of palifermin prophylaxis on hospital costs of transplantation in the trial. This was a retrospective, economic analysis of estimated costs for a previously published clinical trial. Costs were not collected during the trial. Therefore, we estimated the direct medical costs of hospitalization using hospital charges from similar patients' hospitalization charges selected from the National Inpatient Sample, a population-based, nationally representative sample of hospital claims. Costs were estimated from charges using Medicare's state-specific cost-to-charge ratios. These cost estimates were applied to the outcome data (incidence of febrile neutropenia, bacteremia/fungemia, or pneumonia, and use of total parenteral nutrition) from the clinical trial. Patients were those with hematologic malignancies who received high-dose chemotherapy and total-body irradiation with autologous stem cell transplant. We compared the estimated total hospital costs (in 2005 United States dollars) incurred by patients who received palifermin in the clinical trial with those incurred by patients who received placebo. Costs were analyzed from the provider's perspective. The mean cost of a hospital day in this population varied between $2,834, when no adverse outcomes occurred, and $4,663, when all 4 outcomes occurred. Reductions in adverse outcomes and their associated hospital stay offset the acquisition price of palifermin. A nonsignificant mean savings of $3,595 per patient (95% confidence interval: $2,090-$5,103) was observed. In sensitivity analyses, this observation was robust to all plausible values of per diem hospital costs and hypothetic per diem outpatient costs. In addition to its previously demonstrated clinical benefit, palifermin prophylaxis offers a favorable economic profile among patients with hematologic malignancies who receive total body irradiation and autologous stem cell support.
Asunto(s)
Factor 7 de Crecimiento de Fibroblastos/economía , Neoplasias Hematológicas/economía , Trasplante de Células Madre Hematopoyéticas/economía , Hospitalización/economía , Adulto , Ensayos Clínicos Fase III como Asunto/economía , Costos y Análisis de Costo , Método Doble Ciego , Femenino , Factor 7 de Crecimiento de Fibroblastos/administración & dosificación , Neoplasias Hematológicas/terapia , Humanos , Masculino , Medicare , Persona de Mediana Edad , Ensayos Clínicos Controlados Aleatorios como Asunto/economía , Estomatitis/economía , Estomatitis/prevención & control , Trasplante Autólogo , Estados Unidos , Irradiación Corporal Total/economíaRESUMEN
PURPOSE: To study the risk, outcomes, and costs of radiation-induced oral mucositis (OM) among patients receiving radiotherapy (RT) to head and neck primary cancers. METHODS AND MATERIALS: A retrospective cohort consisting of 204 consecutive head-and-neck cancer patients who received RT with or without chemotherapy during 2002 was formed; their records were reviewed for clinical and resource use information. Patients who had received prior therapy, had second primary cancers, or received palliative radiation therapy were excluded. The risk of OM was analyzed by multiple variable logistic regression. The cost of care was computed from the provider's perspective in 2006 U.S. dollars and compared among patients with and without OM. RESULTS: Oral mucositis occurred in 91% of patients; in 66% it was severe (Grade 3-4). Oral mucositis was more common among patients with oral cavity or oropharynx primaries (odds ratio [OR], 44.5; 95% confidence interval [CI], 5.2 to >100; p < 0.001), those who received chemotherapy (OR = 7.8; 95% CI, 1.5-41.6; p = 0.02), and those who were treated with altered fractionation schedules (OR = 6.3; 95% CI, 1.1-35.1; p = 0.03). Patients with OM were significantly more likely to have severe pain (54% vs. 6%; p < 0.001) and a weight loss of > or =5% (60% vs. 17%; p < 0.001). Oral mucositis was associated with an incremental cost of $1700-$6000, depending on the grade. CONCLUSIONS: Head-and-neck RT causes OM in virtually all patients. Oral mucositis is associated with severe pain, significant weight loss, increased resource use, and excess cost. Preventive strategies are needed.